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Summary
 
CC chemokines produced by CD8
 
1
 
 T cells are known to act as HIV-suppressive factors. We
studied the possible role of these chemokines in HIV-1–specific killing of target cells. We found
that the activity of cytotoxic T lymphocytes (CTLs) in CTL lines or freshly isolated peripheral
blood mononuclear cells from HIV-1–infected individuals is markedly enhanced by RANTES
(regulated on activation, normal T cell expressed and secreted) and virtually abolished by an an-
tibody neutralizing RANTES or the RANTES receptor antagonist RANTES(9-68). Lysis was
mediated by CD8
 
1
 
 major histocompatibility complex class I–restricted T cells and was obtained
with target cells expressing epitopes of the HIV-1
 
LAI
 
 proteins Gag, Pol, Env, and Nef. The cy-
tolytic activity observed in the presence or absence of added RANTES could be abolished by
pretreatment of the CTLs with 
 
pertussis
 
 toxin, indicating that the effect is mediated by a G pro-
tein–coupled receptor. The chemokines monocyte chemotactic protein (MCP)-3, MCP-4, and
eotaxin acted like RANTES, whereas macrophage inflammatory protein (MIP)-1
 
a
 
, MIP-1
 
b
 
,
MCP-1, and stromal cell–derived factor 1 were inactive, suggesting a role for the eotaxin recep-
tor, CCR3, and ruling out the involvement of CCR1, CCR2, CCR5, and CXCR4. CTL ac-
tivity was abrogated by an antibody that blocks CCR3, further indicating that specific lysis is
triggered via this chemokine receptor. These observations reveal a novel mechanism for the in-
duction of HIV-1–specific cytotoxicity that depends on RANTES acting via CCR3.
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1
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irus-specific cytolysis is considered a major defense
function of CD8
 
1
 
 T lymphocytes that eliminate pro-
ductively infected cells and control the viral load during the
asymptomatic stages after HIV infection (1). HIV-1–spe-
cific CTLs have been studied extensively, and it has been
shown that they are present in high numbers in the blood
and and tissues (2–4). However, specific CTL activity de-
clines with the development of AIDS (5, 6). CD8
 
1
 
 T cells
are an important source of chemokines that were shown to
inhibit HIV entry into CD4-bearing cells and to limit in-
fection in vitro (7) and in vivo (8). On the other hand,
chemokines are potent attractants of T lymphocytes and
NK cells (9) and could, therefore, enhance antiviral effector
functions by stimulating cytotoxicity. This action would
differ from the well-established role of some chemokines as
competitors for HIV coreceptor usage (10).
Monitoring of specific cytolytic activity is a way to assess
the antiviral defense of HIV-1–infected individuals (11,
12). Activated, CD8
 
1
 
 HIV-1–specific CTLs are known to
produce interferons and chemokines (13), but other factors
or mechanisms may contribute to their overall HIV-1–sup-
pressive activity (7, 14). We have now studied the effects of
chemokines on PBMCs and PBMC-derived, HIV-1–spe-
cific CTL lines generated from HIV-1–infected individuals
who were monitored for several years. We present data in-
dicating that the HIV-1–specific lytic activity of patient-
derived CTLs is enhanced by RANTES (regulated on acti-
vation, normal T cell expressed and secreted), which acts
on the CTLs through the chemokine receptor CCR3.
 
Materials and Methods
 
HIV-1–infected Donors.
 
The donors of PBMCs used to establish
CTL lines and target cells were eight HLA-typed, HIV-1–infected
patients from the French cohort IMMUNOCO with CD4
 
1
 
 T
lymphocyte counts between 150 and 1,050/
 
m
 
l. They were re-
 
V
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cruited in 1991 and were followed for 5 yr on the basis of clinical
and functional tests.
 
Generation of HIV-1–specific CTL Lines.
 
CTL lines were pre-
pared according to established methods (11, 12). PBMCs were
isolated from the venous blood of HIV-1–infected individuals by
centrifugation in Ficoll-Hypaque density gradients (Eurobio, Les
Ulis, France) and were activated overnight with 1 
 
m
 
g/ml PHA
(HA-16; Murex Diagnostic Ltd., Dartford, England). Polyspecific
CTL lines were generated by coculture with irradiated autologous
PHA blasts, and CTL lines specific for the Pol epitope of HIV-1
 
LAI
 
(amino acid 476–484) by coculture with irradiated autologous
PHA blasts that were pre-incubated for 2 h at 37
 
8
 
C with 10 
 
m
 
M of
the synthetic peptide 476–484 (15). The appropriate irradiated
PHA blasts were added every tenth day, and the cocultures were
performed in the presence of recombinant human IL-2 (20 U/ml;
Boehringer Mannheim, Germany) supplied every third day. The
CTLs were used for the cytotoxicity assays after 20 d of coculture.
 
Target Cells.
 
Three types of target cells were used: autologous
EBV-transformed lymphoblastoid B cell lines infected with vac-
cinia virus expressing the HIV-1
 
LAI
 
 proteins Gag, Pol, or Env; au-
tologous EBV-transformed lymphoblastoid B cell lines pulsed
with the synthetic peptide 476–484 corresponding to the Pol
epitope of HIV-1
 
LAI
 
; and the human plasmocytoid cell line Hmy
cotransfected with the HLA-A2 and the HIV-1
 
LAI
 
 nef genes. The
EBV-transformed lymphoblastoid B cell lines were established for
each CTL donor. Infection with wild-type vaccinia virus or with
vaccinia virus expressing the HIV-1
 
LAI
 
 proteins Gag, Pol, or Env
(Transgene, Strasbourg, France) was performed for 18 h at 37
 
8
 
C
at a multiplicity of 5 PFU/cell. Pulsing was performed with 10
 
m
 
M of the synthetic peptide 476–484 for 2 h at 37
 
8
 
C using EBV-
transformed cells already labeled with 
 
51
 
Cr (12). EBV-trans-
formed cells infected with wild-type vaccinia virus or not pulsed
with the synthetic Pol peptide and Hmy cells transfected with the
HLA-A2 gene alone were used as the corresponding controls.
The Hmy cell lines transfected with the HLA-A2 or HLA-A2
and the HIV-1
 
LAI
 
 nef genes (16, 17) were provided by Dr. W.
Biddison (National Institutes of Health, Bethesda, MD).
 
HIV-1–specific CTL Activity.
 
The target cells were labeled for
2 h at 37
 
8
 
C with 100 
 
m
 
Ci per 10
 
6
 
 cells Na
 
51
 
Cr (Amersham, Les
Ulis, France), and washed twice with culture medium. The target
cells were distributed in round-bottomed 96-well microtiter plates
(4 
 
3
 
 10
 
3
 
 cells per well), and the effector cells were added at E/T
ratios ranging between 120:1 and 3:1. The plates were centrifuged
at 300 rpm for 2 min and incubated for 4 h at 37
 
8
 
C. The superna-
tants were then collected and 
 
51
 
Cr-release was measured in a
gamma counter. The relative specific 
 
51
 
Cr-release was calculated as
previously described (12). Values for spontaneous 
 
51
 
Cr-release,
which are deducted in the calculation, were between 10 and 20%
of the total incorporated radioactivity. The results are presented
after subtraction of the nonspecific lysis obtained with control tar-
gets. All experiments were performed in triplicate. SE of triplicates
was always 
 
,
 
5% of the mean value and was omitted for clarity.
 
NK and Lymphokine-activated Killer Cell Generation and Activity.
 
PBMCs from healthy donors were isolated by centrifugation in a
Ficoll-Hypaque density gradient and were immediately tested for
NK activity on K562 target cells. Alternatively, the PBMCs were
cultured for 48 h with 100 U/ml of recombinant IL-2 and tested
for lymphokine-activated killer (LAK) activity on Daudi target
cells. The experiments were performed at E/T ratios ranging be-
tween 70:1 and 7:1. The conditions for the Cr release assays were
the same as for the experiments with CTLs.
 
Flow Cytometry.
 
CCR3 expression was assessed on effector
and target cells using anti-CCR3 (see Reagents). For double flu-
 
orescence analysis of PBMCs, 5 
 
3
 
 10
 
5
 
 cells were incubated for 30
min at 4
 
8
 
C with 10 
 
m
 
g of anti-CCR3, washed with PBS, fixed
with 1% paraformaldehyde in PBS, and analyzed on a FACScan
 
Ò
 
flow cytometer (Becton Dickinson, San Jose, CA). 10
 
4
 
 events per
sample were collected and analyzed using the Cellquest software
(Becton Dickinson).
 
Reagents.
 
RPMI 1640 medium (Gibco Life Technologies,
Cergy Pontoise, France) supplemented with 10% heat-inactivated
FCS, and standard concentrations of 
 
l
 
-glutamine, sodium pyru-
vate, penicillin, and streptomycin was used as the medium in all
cultures and for dissolving additions. The chemokines and the
chemokine antagonist RANTES(9-68) were prepared by chemi-
cal synthesis (18). If not stated otherwise they were added to the
assays at the time of mixing effector and target cells. RANTES
determination in cell supernatants was performed by ELISA
(R&D Systems, Minneapolis, MN) and the data were analyzed
using the Softmax program (Molecular Devices, Sunnyvale, CA).
A standard concentration curve was assayed with each analysis.
Four neutralizing monoclonal antibodies were used: anti-RANTES
(R&D Systems, Minneapolis, MN); anti-CCR3 (7B11; LeukoSite,
Cambridge, MA); anti-CD4 (IOT4; Immunotech, Marseille,
France); and anti-CD8 (B9-11; Immunotech). An anti-VLA6
monoclonal of the same isotype (Immunotech) was used as irrele-
vant antibody control. The antibodies were added to the suspen-
sion containing the CTLs shortly before mixing with the targets
at the concentration of 1 
 
m
 
g/ml, which was found, in concentra-
tion-dependence assays, to be sufficient for neutralization. Pre-
treatment of CTLs with 
 
Bordetella pertussis
 
 toxin (Sigma-Aldrich,
St. Quentin Fallavier, France) was performed for 1.5 h at 37
 
8
 
C in
the standard medium, followed by washing.
 
Results and Discussion
 
RANTES Enhances CTL Activity.
 
The effect of RANTES
on HIV-1–specific cytotoxicity was examined using poly-
specific MHC class I–restricted CTL lines established from
HIV-1–infected donors that recognize the HIV-1
 
LAI
 
 Env,
Pol, Gag, or Nef gene products. As shown in Fig. 1 
 
A
 
, the
specific lysis of autologous B cell lines expressing Gag, was
markedly enhanced by RANTES and was suppressed by a
RANTES-neutralizing antibody. Similar effects were ob-
tained when the lytic activity of patient-derived HIV-1–
specific CTLs was tested with two other targets, autologous
B cells pulsed with a HIV-1 Pol peptide (Fig. 1 
 
B
 
) and a
human plasmocytoid cell line, Hmy, cotransfected with the
HLA-A2 and the HIV-1
 
LAI
 
 
 
nef
 
 genes (Fig. 1 
 
C
 
). By con-
trast, neither RANTES nor the RANTES-neutralizing an-
tibody influenced the lysis mediated by blood-derived NK
or LAK cells, as illustrated for NK cells in Fig. 1 
 
D.
 
 As
shown in Fig. 1 
 
E
 
, the enhancing effect of RANTES and
the inhibition of CTL activity by either neutralizing
RANTES or blocking its receptor with the antagonist
RANTES(9-68) were regularly observed with several CTL
lines specific for Gag, Pol, or Env derived from HIV-1–
infected individuals. Together these results indicate that
RANTES was required for the lytic activity of HIV-1–spe-
cific CTLs of the cohort patients. Comparison of CTLs
from different individuals (Fig. 1 
 
E
 
) shows that the effects
were similar for different HIV-1 epitopes presented by the
target cells, and were highly reproducible. The use of dif- 
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ferent types of target cells (Fig. 1, 
 
A–C
 
) indicates that the pro-
cedure used to induce expression of HIV-1–specific epitopes
had no influence on the outcome of the experiments.
The effects of RANTES and RANTES(9-68) were con-
centration dependent (Fig. 2 
 
A
 
). Specific lysis was nearly
doubled at 10 nM RANTES and approached a maximum
between 50 and 100 nM, whereas inhibition by RANTES
(9-68) was observed above 25 nM and was nearly complete
at 50 and 100 nM. On the other hand, no effect was ob-
tained with increasing concentrations of macrophage in-
flammatory protein (MIP)-1
 
a
 
. The concentrations shown
are similar to those required for leukocyte activation by
chemokines and the inhibition of functional responses by
chemokine antagonists (19–21). Since chemokine antago-
nists have lower receptor affinity than the chemokines
themselves (20), it is not surprising that higher concentra-
tions of RANTES(9-68) were required to achieve a bio-
logical effect. As shown in Fig. 2 
 
B
 
, pretreatment of the
CTLs with increasing concentrations of 
 
pertussis
 
 toxin pro-
gressively decreased the cytolytic activity observed in the
presence of RANTES, indicating that the chemokine ef-
fect is mediated by a G protein–coupled receptor (9). 
 
Per-
tussis
 
 toxin also abrogated CTL activity in the absence of
added RANTES (data not shown). To identify the cells re-
sponding to RANTES, effector and target cells were pre-
treated separately before testing cytotoxicity (Fig. 2 
 
C
 
).
Pretreatment of the effector cells with RANTES yielded
similar results as shown in Fig. 1 when the chemokine was
added at the time of mixing effectors and targets. By con-
trast, no changes were observed when the same pretreat-
ment was applied to the target cells. MIP-1
 
a
 
 and MIP-1
 
b
 
,
which are produced by CD8
 
1
 
 T cells together with
RANTES (22, 23), were ineffective, as shown in Fig. 2 
 
C
 
for MIP-1
 
a
 
, suggesting that MIP-1
 
a
 
 and MIP-1
 
b
 
 do not
share the relevant receptor with RANTES. These results
indicate that RANTES acts on the CTLs and has no toxic
or other apparent effect on the target cells. Additional sup-
port for this conclusion comes from the observed inhibi-
tion of the effect of RANTES after pretreatment of the
CTLs with 
 
pertussis
 
 toxin (Fig. 2 
 
B
 
).
 
CTL Activity Mediated by CCR3.
 
RANTES binds to
several receptors. It attracts monocytes (19, 24) and T lym-
phocytes (25) via CCR1, and eosinophils and basophils via
CCR3 (26, 27) and acts on T lymphocytes via CCR5 (28).
CCR4 was also reported as a candidate receptor (29), but
was later shown to bind a novel CC chemokine called
TARC (30). To identify the receptor involved in HIV-1–
specific CTL activity, we tested the effect of several well-
characterized chemokines. As shown in Fig. 3, RANTES
could be substituted by eotaxin, monocyte chemotactic
protein (MCP)-3 and MCP-4, but not by MIP-1
 
a
 
, MCP-1,
or stromal cell–derived factor (SDF)-1. This suggests that
the observed HIV-1–specific CTL activity depends on
CCR3 and rules out effects via CCR1, CCR2, CCR5,
and CXCR4. To definitively prove the involvement of
CCR3, we used a monoclonal antibody that selectively
blocks the function of this receptor (26). Fig. 3 shows that tar-
get cell lysis was abrogated in the presence of the antibody
Figure 1. RANTES enhances HIV-1–specific CTL activity. (A)
Transformed autologous B cells infected with recombinant vaccinia virus
expressing Gag HIV-1 antigens were used as targets. Lysis by HIV-1–spe-
cific CTLs was determined in the presence of 25 nM RANTES (closed
squares), 1 mg/ml anti-RANTES (open circles), or without additions (closed
circles). No lysis was obtained in the presence or absence of 25 nM
RANTES (open squares and closed triangles, respectively) when transformed
autologous B cells infected with wild-type recombinant vaccinia virus
were used as targets. Similar effects were obtained in eight experiments
with CTLs from different HIV-1–infected donors. (B) Transformed au-
tologous B cells preincubated with the synthetic peptide 476–484 corre-
sponding to the Pol epitope of HIV-1LAI were used as targets. Lysis by
HIV-1–specific CTLs was determined in the presence of 25 nM
RANTES (closed squares), 25 nM RANTES(9-68) (open squares), 1 mg/ml
anti-RANTES (open circles), or without additions (closed circles). Data from
one experiment. (C) Human plasmocytoid cells Hmy cotransformed with
the HLA-A2 and the HIV-1LAI nef genes were used as targets. Lysis by
HIV-1–specific CTLs was determined in the presence of 25 nM
RANTES (closed squares), 25 nM RANTES(9-68) (open squares), 1 mg/ml
anti-RANTES (open circles), or without additions (closed circles). The data
are representative for two experiments. (D) RANTES does not affect the
lytic activity of NK cells. Lysis of K562 target cells by NK cells obtained
from venous blood of healthy donors was determined in the presence of
25 nM RANTES (closed squares), 1 mg/ml anti-RANTES (open circles), or
without additions (open squares). The data are representative for four ex-
periments. (E) Effects of 25 nM RANTES, 1 mg/ml anti-RANTES and
25 nM RANTES(9268) on the activity of HIV-1–specific CTLs from
eight different donors. Transformed autologous B cells infected with re-
combinant vaccinia virus expressing Gag (squares), Pol (circles), or Env (tri-
angles) were used as targets. Data are shown for an E/T ratio of 40:1. The
straight lines connect the lytic activity values obtained in the absence (2)
or presence (1) of the added reagent as indicated.612 CTL Activity Mediated by RANTES via CCR3
confirming that HIV-1–specific cytotoxicity is mediated by
chemokines that act via CCR3. Anti-CCR3 also prevented
the lysis of autologous B cells pulsed with a HIV-1 Pol peptide
476–484 and of the Hmy plasmocytoid cells expressing HLA-
A2 and HIV-1LAI Nef, but had no effect on the lysis by NK
cells (data not shown). We tested the expression of CCR3 in
several HIV-1–specific CTL lines established from HIV-1–
infected individuals. The receptor was detectable in all lines,
and the percentage of positive cells varied between 3 and 10
depending on the donor. In no instance CCR3 was detected
on the target cells (data not shown). Although several
chemokines that bind to CCR3 enhanced CTL activity,
RANTES appears to be the biologically relevant stimulus,
since lysis was virtually abolished when this chemokine was
selectively neutralized with the anti-RANTES antibody. It
has been previously reported that CD81 T cells produce
RANTES and other CC chemokines (31–34). We have de-
termined the production of RANTES by two CTL lines for
the duration of the cytotoxicity assay at an E/T ratio of 120:1,
and found concentrations of 52 6 5 and 138 6 22 pg/ml 6
SD in the culture medium under conditions that yielded 20
and 40% specific lysis, respectively. These concentrations are
considerably lower than those added in this study to enhance
lysis. The low level of RANTES detected in these assays may
be related to the weak lytic activity observed even at high E/T
ratios. On the other hand, RANTES is likely to bind to CCR3
as it is released by the producing cells, and the assay in the
supernatant may underestimate the effective concentrations.
After having shown that RANTES is a major mediator
of lysis by CTL lines derived from HIV-1–infected pa-
tients, it was important to assess whether the activity of
freshly isolated PBMCs was also RANTES-dependent. As
shown in Fig. 4, HIV-1–specific lysis by PBMCs that were
freshly isolated from infected individuals was enhanced by
RANTES and virtually abolished by antibodies that neu-
tralize RANTES or block CCR3. In addition, Fig. 4
shows that CTL lines established from the PBMCs of both
donors lysed autologous but not mismatched targets. The
lytic activity was abrogated by anti-CD8 antibodies, both
in the presence and absence of RANTES indicating that it
was mediated by CD81 T lymphocytes. Anti-CD4 anti-
bodies, by contrast, were without effect (data not shown).
This study shows that RANTES mediates the HIV-1–
specific killing of target cells by MHC-restricted CD81 T
lymphocytes through a mechanism that depends on the
chemokine receptor CCR3. It is of interest that RANTES
is produced by CD81 T cells after antigen-specific stimula-
tion (35) and that CCR3 is expressed in CD41 and CD81
Figure 2. (A) Concentration
dependence of the effect of
RANTES on HIV-1–specific
cytolysis. Transformed autolo-
gous B cells infected with re-
combinant vaccinia virus ex-
pressing Gag were used as
targets. Lysis by HIV-1–specific
CTLs was assessed at an E/T
ratio of 120:1 in the presence
of increasing concentrations of
RANTES (closed circles), the an-
tagonist RANTES(9-68) (open
circles), or MIP-1a (closed trian-
gles). The data are representa-
tive for two experiments. (B)
Effect of B. pertussis toxin. The
effector cells were pretreated with RANTES in the absence (closed circles) or the presence (open circles) of pertussis toxin, washed, and then mixed with tar-
get cells expressing HIV-1 Pol protein. The toxin concentration was 10, 100, 1,000, or 5,000 ng/ml (open circles, top to bottom). The data are representa-
tive for four experiments. (C) RANTES acts on the HIV-1–specific CTLs but not on the target cells. Lysis was assessed at a similar E/T ratio after pretreat-
ment of the effector (white bars) or the target cells (hatched bars) with RANTES, MIP-1a (all 25 nM) or without additions. Pretreatment was performed
for 1 h at 378C followed by washing, immediately before the Cr-release assay. The data are representative for two experiments.
Figure 3. Lysis by HIV-1–specific CTLs is
mediated by CCR3. Transformed autologous B
cells infected with recombinant vaccinia virus
expressing Gag were used as target cells. Lysis
by HIV-1–specific CTL lines obtained from
two individuals (A and B) was determined at an
E/T ratio of 120:1 in the presence of different
chemokines (all 25 nM), 25 nM RANTES(9-
68), 1 mg/ml anti-RANTES, 1 mg/ml anti-
CCR3, 1 mg/ml anti-CCR3 plus 25 nM
RANTES, or without additions. Similar effects
were obtained in eight experiments with CTLs
from different HIV-1–infected donors.613 Hadida et al. Brief Definitive Report
T lymphocytes (36). MIP-1a, MIP-1b, RANTES, and
MCP-1 were reported to enhance the proliferation of hu-
man T cells in response to anti-CD3 and of T cell clones
challenged with the relevant antigen (37), suggesting a role
of CC chemokines in the activation of polyclonal and anti-
gen-specific cytotoxicity (38). A costimulatory function of
RANTES cannot be ruled out although the selectivity ob-
served in this study suggests a different mechanism. Our
observations reveal a new facet of the antiviral properties of
RANTES. The involvement of CCR3 suggests the possi-
bility to enhance its expression by CD81 effector T cells in
order to prevent the decline of CTL activity in AIDS and
to improve cellular defense in other immunodeficiencies.
In addition, retroviral gene transduction approaches could
be used to regulate the endogenous expression of
RANTES or RANTES-inducing cytokines.
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